Conditions: Hepatitis C HIV
Keywords: HCV HIV
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 26
Healthy volunteers: yes

Brief summary:
The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine. The investigators believe that etravirine's drug concentrations will be increased when administered in combination with boceprevir. Additionally, the investigators believe that boceprevir and etravirine are safe when administered alone or in combination.

Detailed description:
To investigate the potential for drug interactions between boceprevir and etravirine, participants will receive each drug alone and the drugs in combination for 11-14 days. The pharmacokinetics of boceprevir and etravirine when given in combination vs. alone will be compared.

Arms:
arm 1: Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine. arm 2: Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only. arm 3: Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine. arm 4: Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only. arm 5: Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only. arm 6: Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.

Interventions: intervention 1: boceprevir; etravirine
Intervention descriptions: intervention 1: boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.

Protocol document: